Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the Beamcath (R) technique

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Löfroth Per Olov) > (2005-2009) > Five-year prospecti...

1 av 9
Föregående post
Nästa post
Till träfflistan

Fransson, PerUmeå universitet,Onkologi (författare)

Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the Beamcath (R) technique

Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

Elsevier,2006
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:umu-13367
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-13367URI
https://doi.org/10.1016/j.ijrobp.2006.05.007DOI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Purpose: Late side effects were prospectively evaluated up to 5 years after dose-escalated external beam radiotherapy (EBRT) and were compared with a previously treated series with conventional conformal technique.Methods and Materials: Bladder and bowel symptoms were prospectively evaluated with the Prostate Cancer Symptom Scale (PCSS) questionnaire up to 5 years posttreatment. In all, 257 patients completed the questionnaire 5 years posttreatment. A total of 168 patients were treated with the conformal technique at doses <71 Gy, and 195 were treated with the dose-escalated stereotactic BeamCath® technique comprising three dose levels: 74 Gy (n = 68), 76 Gy (n = 74), and 78 Gy (n = 53).Results: For all dose groups analyzed together, 5 years after treatment, urinary starting problems decreased and urinary incontinence increased in comparison to baseline values. No increase in other bladder symptoms or frequency was detected. When comparing dose groups after 5 years, both the 74-Gy and 78-Gy groups reported increased urinary starting problems compared with patients given the conventional dose (<71 Gy). No increased incontinence was seen in the 76-Gy or the 78-Gy groups. Bowel symptoms were slightly increased during the follow-up period in comparison to baseline. Dose escalation with stereotactic EBRT (74–78 Gy) did not increase gastrointestinal late side effects after 5 years in comparison to doses <71 Gy.Conclusion: Dose-escalated EBRT with the BeamCath® technique with doses up to 78 Gy is tolerable, and the toxicity profile is similar to that observed with conventional doses <71 Gy.

Biuppslag (personer, institutioner, konferenser, titlar ...)

Bergström, PerUmeå universitet,Onkologi(Swepub:umu)pebe0049 (författare)
Löfroth, Per-OlovUmeå universitet,Radiofysik (författare)
Widmark, AndersUmeå universitet,Onkologi(Swepub:umu)anwi0004 (författare)
Umeå universitetOnkologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:International Journal of Radiation Oncology, Biology, Physics: Elsevier66:2, s. 430-4380360-30161879-355X

Internetlänk

Hitta via bibliotek

International Journal of Radiation Oncology, Biology, Physics (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 9
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Fransson, Per; Bergström, Per; Löfroth, Per-Olo ...; Widmark, Anders

Artiklar i publikationen: International Jo ...

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se